Within the EU and the US, approximately 20.5 million adults and children suffer from moderate to severe eczema. In the Netherlands there are 160,000 people with a moderate to severe form of this chronic condition. The use of blue light therapy is an effective, safe and cost-efficient alternative to existing therapies. Based on the experience gained from the Light & Health division at Philips, developer Phlecs launched an MVP in 2022, which allows patients to undergo blue light therapy in a clinical setting. Due to market demand for a home treatment solution, Phlecs is going to develop a home device for blue light therapy, the Phlecs Full Body Home. Within the new project, Phlecs collaborates with project partners Unitron Systems, Stichting Bravis Hospital and Care Innovation Center. For severe patients, blue light therapy can be supplemented with balneotherapy, further increasing the effectiveness of treatment.